Revised International Prognostic Scoring System for Myelodysplastic Syndrome

The Revised International Prognostic Scoring System stratifies untreated MDS by cytogenetics, marrow blasts, and depth of cytopenias to predict survival and AML progression risk.

Cytogenetic group
Very good: del(11q) or -Y0Good: normal karyotype, del(20q), del(5q), del(12p), or double including del(5q)+1Intermediate: +8, del(7q), i(17q), +19, or any other single or double independent clone+2Poor: -7, inv(3)/t(3q)/del(3q), double including -7/del(7q), or complex (3 abnormalities)+3Very poor: complex >3 abnormalities+4
Medullary blasts, %
≤ 20> 2 to < 5+15 to 10+2
Hemoglobin, g/dL (g/L)
≥10 (≥100)08 to < 10 (<100)+1< 8 (<80)+1.5
Platelets, x10^3/ul or 10^9/L
≥100050 to <100+0.5<50+1
ANC, x10^3/uL or 10^9/L
≥0.80<0.8+0.5

Indicaciones de Uso

Used to risk‑stratify newly diagnosed, untreated MDS and determine overall survival, leukemia‑free survival, and AML‑transformation risk, guiding lower‑ vs higher‑risk management and timing of allo‑HCT. Incorporates cytopenias, blasts, cytogenetics, giving more precise prognostication than older systems and improving selection of candidates for early transplantation (validated in large cohorts 1 [Level II evidence]; 2 [Level II evidence]).

Información y Precauciones

Stratifies survival and AML progression risk using blasts, cytopenias, and cytogenetics but fails to incorporate somatic mutations, limiting precision—especially for TP53, SF3B1, and complex-karyotype disease (major limitation emphasized by genomic-era analyses 1 [Level III evidence]). Real‑world data show reclassification in ~46% when switching to IPSS‑M, with markedly better prognostic discrimination 2 [Level II evidence]. Should be used cautiously in treated patients and does not reliably predict treatment response or post‑HCT outcomes.